|
Gene: ERBB2 |
Gene summary for ERBB2 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ERBB2 | Gene ID | 2064 |
Gene name | erb-b2 receptor tyrosine kinase 2 | |
Gene Alias | CD340 | |
Cytomap | 17q12 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | P04626 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
2064 | ERBB2 | P1T-E | Human | Esophagus | ESCC | 2.79e-20 | 8.19e-01 | 0.0875 |
2064 | ERBB2 | P2T-E | Human | Esophagus | ESCC | 5.28e-17 | 3.62e-01 | 0.1177 |
2064 | ERBB2 | P4T-E | Human | Esophagus | ESCC | 7.69e-13 | 2.44e-01 | 0.1323 |
2064 | ERBB2 | P5T-E | Human | Esophagus | ESCC | 1.98e-11 | 9.38e-03 | 0.1327 |
2064 | ERBB2 | P8T-E | Human | Esophagus | ESCC | 7.69e-54 | 1.19e+00 | 0.0889 |
2064 | ERBB2 | P9T-E | Human | Esophagus | ESCC | 1.17e-05 | 1.89e-02 | 0.1131 |
2064 | ERBB2 | P10T-E | Human | Esophagus | ESCC | 2.56e-06 | 1.78e-01 | 0.116 |
2064 | ERBB2 | P11T-E | Human | Esophagus | ESCC | 2.33e-11 | 3.78e-01 | 0.1426 |
2064 | ERBB2 | P12T-E | Human | Esophagus | ESCC | 2.91e-16 | 3.66e-01 | 0.1122 |
2064 | ERBB2 | P15T-E | Human | Esophagus | ESCC | 1.34e-17 | 5.45e-01 | 0.1149 |
2064 | ERBB2 | P16T-E | Human | Esophagus | ESCC | 1.06e-13 | 1.78e-01 | 0.1153 |
2064 | ERBB2 | P17T-E | Human | Esophagus | ESCC | 1.90e-04 | 4.85e-01 | 0.1278 |
2064 | ERBB2 | P19T-E | Human | Esophagus | ESCC | 3.39e-02 | 5.61e-01 | 0.1662 |
2064 | ERBB2 | P20T-E | Human | Esophagus | ESCC | 2.58e-14 | 2.53e-01 | 0.1124 |
2064 | ERBB2 | P21T-E | Human | Esophagus | ESCC | 8.36e-27 | 3.82e-01 | 0.1617 |
2064 | ERBB2 | P22T-E | Human | Esophagus | ESCC | 1.75e-29 | 1.43e-01 | 0.1236 |
2064 | ERBB2 | P23T-E | Human | Esophagus | ESCC | 8.45e-15 | 3.49e-01 | 0.108 |
2064 | ERBB2 | P24T-E | Human | Esophagus | ESCC | 3.85e-14 | 1.51e-01 | 0.1287 |
2064 | ERBB2 | P26T-E | Human | Esophagus | ESCC | 8.99e-13 | 1.05e-01 | 0.1276 |
2064 | ERBB2 | P27T-E | Human | Esophagus | ESCC | 1.69e-22 | 3.71e-01 | 0.1055 |
Page: 1 2 3 4 5 6 7 8 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00064179 | Breast | Precancer | regulation of translation | 67/1080 | 468/18723 | 4.71e-12 | 7.64e-10 | 67 |
GO:00457279 | Breast | Precancer | positive regulation of translation | 32/1080 | 136/18723 | 5.89e-12 | 9.27e-10 | 32 |
GO:00342509 | Breast | Precancer | positive regulation of cellular amide metabolic process | 33/1080 | 162/18723 | 1.72e-10 | 1.77e-08 | 33 |
GO:00457859 | Breast | Precancer | positive regulation of cell adhesion | 52/1080 | 437/18723 | 5.74e-07 | 2.49e-05 | 52 |
GO:00420609 | Breast | Precancer | wound healing | 48/1080 | 422/18723 | 5.48e-06 | 1.63e-04 | 48 |
GO:00421107 | Breast | Precancer | T cell activation | 52/1080 | 487/18723 | 1.37e-05 | 3.42e-04 | 52 |
GO:19037069 | Breast | Precancer | regulation of hemopoiesis | 41/1080 | 367/18723 | 3.95e-05 | 8.52e-04 | 41 |
GO:00506736 | Breast | Precancer | epithelial cell proliferation | 46/1080 | 437/18723 | 6.02e-05 | 1.23e-03 | 46 |
GO:00508637 | Breast | Precancer | regulation of T cell activation | 37/1080 | 329/18723 | 8.04e-05 | 1.56e-03 | 37 |
GO:19049519 | Breast | Precancer | positive regulation of establishment of protein localization | 36/1080 | 319/18723 | 9.30e-05 | 1.75e-03 | 36 |
GO:00071597 | Breast | Precancer | leukocyte cell-cell adhesion | 40/1080 | 371/18723 | 1.07e-04 | 1.94e-03 | 40 |
GO:19021055 | Breast | Precancer | regulation of leukocyte differentiation | 32/1080 | 279/18723 | 1.66e-04 | 2.74e-03 | 32 |
GO:00506786 | Breast | Precancer | regulation of epithelial cell proliferation | 40/1080 | 381/18723 | 1.88e-04 | 3.03e-03 | 40 |
GO:00224079 | Breast | Precancer | regulation of cell-cell adhesion | 45/1080 | 448/18723 | 2.12e-04 | 3.30e-03 | 45 |
GO:19031313 | Breast | Precancer | mononuclear cell differentiation | 43/1080 | 426/18723 | 2.61e-04 | 3.84e-03 | 43 |
GO:19030377 | Breast | Precancer | regulation of leukocyte cell-cell adhesion | 36/1080 | 336/18723 | 2.61e-04 | 3.84e-03 | 36 |
GO:00420633 | Breast | Precancer | gliogenesis | 33/1080 | 301/18723 | 3.06e-04 | 4.40e-03 | 33 |
GO:00160497 | Breast | Precancer | cell growth | 46/1080 | 482/18723 | 5.63e-04 | 7.16e-03 | 46 |
GO:19038299 | Breast | Precancer | positive regulation of cellular protein localization | 30/1080 | 276/18723 | 6.48e-04 | 7.99e-03 | 30 |
GO:00066059 | Breast | Precancer | protein targeting | 33/1080 | 314/18723 | 6.50e-04 | 7.99e-03 | 33 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0453018 | Breast | Precancer | Tight junction | 31/684 | 169/8465 | 1.13e-05 | 1.26e-04 | 9.64e-05 | 31 |
hsa0406616 | Breast | Precancer | HIF-1 signaling pathway | 23/684 | 109/8465 | 1.51e-05 | 1.59e-04 | 1.22e-04 | 23 |
hsa0520514 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
hsa0452018 | Breast | Precancer | Adherens junction | 17/684 | 93/8465 | 1.11e-03 | 7.57e-03 | 5.80e-03 | 17 |
hsa052309 | Breast | Precancer | Central carbon metabolism in cancer | 13/684 | 70/8465 | 3.57e-03 | 2.17e-02 | 1.66e-02 | 13 |
hsa0453019 | Breast | Precancer | Tight junction | 31/684 | 169/8465 | 1.13e-05 | 1.26e-04 | 9.64e-05 | 31 |
hsa0406617 | Breast | Precancer | HIF-1 signaling pathway | 23/684 | 109/8465 | 1.51e-05 | 1.59e-04 | 1.22e-04 | 23 |
hsa0520515 | Breast | Precancer | Proteoglycans in cancer | 30/684 | 205/8465 | 1.00e-03 | 7.18e-03 | 5.50e-03 | 30 |
hsa0452019 | Breast | Precancer | Adherens junction | 17/684 | 93/8465 | 1.11e-03 | 7.57e-03 | 5.80e-03 | 17 |
hsa0523012 | Breast | Precancer | Central carbon metabolism in cancer | 13/684 | 70/8465 | 3.57e-03 | 2.17e-02 | 1.66e-02 | 13 |
hsa0453024 | Breast | IDC | Tight junction | 38/867 | 169/8465 | 2.07e-06 | 3.20e-05 | 2.39e-05 | 38 |
hsa0520523 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0406623 | Breast | IDC | HIF-1 signaling pathway | 22/867 | 109/8465 | 1.36e-03 | 1.00e-02 | 7.50e-03 | 22 |
hsa0521921 | Breast | IDC | Bladder cancer | 10/867 | 41/8465 | 7.07e-03 | 3.54e-02 | 2.65e-02 | 10 |
hsa045109 | Breast | IDC | Focal adhesion | 32/867 | 203/8465 | 8.60e-03 | 4.23e-02 | 3.17e-02 | 32 |
hsa0453034 | Breast | IDC | Tight junction | 38/867 | 169/8465 | 2.07e-06 | 3.20e-05 | 2.39e-05 | 38 |
hsa0520533 | Breast | IDC | Proteoglycans in cancer | 42/867 | 205/8465 | 7.69e-06 | 9.99e-05 | 7.48e-05 | 42 |
hsa0406633 | Breast | IDC | HIF-1 signaling pathway | 22/867 | 109/8465 | 1.36e-03 | 1.00e-02 | 7.50e-03 | 22 |
hsa0521931 | Breast | IDC | Bladder cancer | 10/867 | 41/8465 | 7.07e-03 | 3.54e-02 | 2.65e-02 | 10 |
hsa0451013 | Breast | IDC | Focal adhesion | 32/867 | 203/8465 | 8.60e-03 | 4.23e-02 | 3.17e-02 | 32 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
AREG | EGFR_ERBB2 | AREG_EGFR_ERBB2 | EGF | Breast | DCIS |
HBEGF | EGFR_ERBB2 | HBEGF_EGFR_ERBB2 | EGF | Breast | DCIS |
EREG | EGFR_ERBB2 | EREG_EGFR_ERBB2 | EGF | Breast | DCIS |
NRG1 | ERBB2_ERBB3 | NRG1_ERBB2_ERBB3 | NRG | Breast | DCIS |
AREG | EGFR_ERBB2 | AREG_EGFR_ERBB2 | EGF | Cervix | CC |
HBEGF | EGFR_ERBB2 | HBEGF_EGFR_ERBB2 | EGF | Cervix | CC |
HBEGF | ERBB2_ERBB4 | HBEGF_ERBB2_ERBB4 | EGF | Cervix | CC |
NRG1 | ERBB2_ERBB4 | NRG1_ERBB2_ERBB4 | NRG | Cervix | CC |
NRG4 | ERBB2_ERBB4 | NRG4_ERBB2_ERBB4 | NRG | Cervix | CC |
NRG1 | ERBB2_ERBB3 | NRG1_ERBB2_ERBB3 | NRG | Cervix | Precancer |
NRG1 | ERBB2_ERBB3 | NRG1_ERBB2_ERBB3 | NRG | CRC | AD |
TGFA | EGFR_ERBB2 | TGFA_EGFR_ERBB2 | EGF | CRC | AD |
NRG1 | ERBB2_ERBB3 | NRG1_ERBB2_ERBB3 | NRG | CRC | ADJ |
TGFA | EGFR_ERBB2 | TGFA_EGFR_ERBB2 | EGF | CRC | ADJ |
AREG | EGFR_ERBB2 | AREG_EGFR_ERBB2 | EGF | CRC | ADJ |
AREG | EGFR_ERBB2 | AREG_EGFR_ERBB2 | EGF | CRC | FAP |
NRG1 | ERBB2_ERBB3 | NRG1_ERBB2_ERBB3 | NRG | CRC | FAP |
TGFA | EGFR_ERBB2 | TGFA_EGFR_ERBB2 | EGF | CRC | MSI-H |
AREG | EGFR_ERBB2 | AREG_EGFR_ERBB2 | EGF | CRC | MSI-H |
HBEGF | EGFR_ERBB2 | HBEGF_EGFR_ERBB2 | EGF | CRC | MSS |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ERBB2 | SNV | Missense_Mutation | rs121913471 | c.2329N>T | p.Val777Leu | p.V777L | P04626 | protein_coding | deleterious(0.05) | benign(0.036) | TCGA-4H-AAAK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | CR |
ERBB2 | SNV | Missense_Mutation | c.2033N>A | p.Arg678Gln | p.R678Q | P04626 | protein_coding | tolerated(0.19) | benign(0.103) | TCGA-A2-A0T6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
ERBB2 | SNV | Missense_Mutation | c.2263N>A | p.Leu755Met | p.L755M | P04626 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0T6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
ERBB2 | SNV | Missense_Mutation | c.2264N>G | p.Leu755Trp | p.L755W | P04626 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A2-A0T6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD | |
ERBB2 | SNV | Missense_Mutation | c.929C>T | p.Ser310Phe | p.S310F | P04626 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A2-A3XV-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR | |
ERBB2 | SNV | Missense_Mutation | c.926N>C | p.Gly309Ala | p.G309A | P04626 | protein_coding | deleterious(0.02) | probably_damaging(0.997) | TCGA-A8-A06Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ERBB2 | SNV | Missense_Mutation | c.2524N>A | p.Val842Ile | p.V842I | P04626 | protein_coding | deleterious(0) | possibly_damaging(0.906) | TCGA-A8-A08Z-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | |
ERBB2 | SNV | Missense_Mutation | rs121913470 | c.2264N>C | p.Leu755Ser | p.L755S | P04626 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A0A6-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | epirubicin | CR |
ERBB2 | SNV | Missense_Mutation | rs121913470 | c.2264T>C | p.Leu755Ser | p.L755S | P04626 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A8-A0AB-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
ERBB2 | SNV | Missense_Mutation | rs121913470 | c.2264T>C | p.Leu755Ser | p.L755S | P04626 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AC-A3YI-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | cytoxan | CR |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | EMODIN | EMODIN | 9671406 | |
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | CHEMBL2108029 | ERTUMAXOMAB | ||
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | Talazoparib | TALAZOPARIB | ||
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | inhibitor | CHEMBL3545063 | OSIMERTINIB MESYLATE | |
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | inhibitor | CHEMBL1645462 | AC-480 | |
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | AC480 | AC-480 | ||
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | antibody | PERTUZUMAB | PERTUZUMAB | |
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | trastuzumab emtansine | |||
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | GEMCITABINE | GEMCITABINE | 15581051 | |
2064 | ERBB2 | KINASE, DRUGGABLE GENOME, CLINICALLY ACTIONABLE, DRUG RESISTANCE, TYROSINE KINASE | Neratinib | NERATINIB | 28274957,28679771,22908275,26874901,23953056,28363995,26333383,27078022,28539475,24323026,23220880,27697991,26243863 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 |